NasdaqCM - Delayed Quote USD

Bluejay Diagnostics, Inc. (BJDX)

Get top stock picks

0.8324 -0.0165 (-1.94%)

At close: September 4 at 4:00:01 PM EDT

0.8299 -0.0025 (-0.30%)

After hours: September 4 at 7:30:03 PM EDT

Get top stock picks

Loading Chart for BJDX

Chart Range Bar

Interval:

In partnership with ChartIQ

Bluejay Diagnostics Reports Q2 2026 Results; Strengthened Balance Sheet Supports Advancement of Symphony™ IL-6 Toward Regulatory Submission and Commercialization

Bluejay Diagnostics Reports Q2 2026 Results; Strengthened Balance Sheet Supports Advancement of Symphony™ IL-6 Toward Regulatory Submission and Commercialization

Bluejay Diagnostics Announces Successful Completion of Enrollment in the SYMON-II Multicenter Clinical Validation Study

Bluejay Diagnostics Announces Successful Completion of Enrollment in the SYMON-II Multicenter Clinical Validation Study

Bluejay Diagnostics Provides First Quarter 2026 Corporate Update

Bluejay Diagnostics Provides First Quarter 2026 Corporate Update

Bluejay Diagnostics Announces Closing of Up to $23.7 Million Private Placement Priced At-The-Market Under Nasdaq Rules

Bluejay Diagnostics Announces Closing of Up to $23.7 Million Private Placement Priced At-The-Market Under Nasdaq Rules

Bluejay Diagnostics and Argonaut Manufacturing Services Announce Strategic Partnership

Bluejay Diagnostics and Argonaut Manufacturing Services Announce Strategic Partnership

Bluejay Diagnostics Announces up to $23.6 Million Private Placement Priced At-the-Market Under Nasdaq Rules

Bluejay Diagnostics Announces up to $23.6 Million Private Placement Priced At-the-Market Under Nasdaq Rules

Bluejay Diagnostics Announces Closing of $4.5 Million Private Placement Priced At-The-Market Under Nasdaq Rules

Bluejay Diagnostics Announces Closing of $4.5 Million Private Placement Priced At-The-Market Under Nasdaq Rules

Bluejay Diagnostics, Inc. Announces Completion of 624 Patient Enrollments in SYMON-II Pivotal Clinical Trial

Bluejay Diagnostics, Inc. Announces Completion of 624 Patient Enrollments in SYMON-II Pivotal Clinical Trial

Bluejay Announces Abstract Accepted for Presentation at the 2026 Society of Academic Emergency Medicine (SAEM) Annual Meeting

Bluejay Announces Abstract Accepted for Presentation at the 2026 Society of Academic Emergency Medicine (SAEM) Annual Meeting

NorthStrive Fund II LP Issues Open Letter to the Board and Shareholders of Bluejay Diagnostics

NorthStrive Fund II LP Issues Open Letter to the Board and Shareholders of Bluejay Diagnostics

Bluejay Diagnostics Provides Corporate Update and 2026 Strategic Outlook

Bluejay Diagnostics Provides Corporate Update and 2026 Strategic Outlook

VERO

WOK

TIVC

NUWE

TNON

FEED

PAVM

IVF

POAS

PFSA

Mobilize your Website

View Site in Mobile | Classic

Share by: